Consensus Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.5 ^USD	+1.35%		0.00%	-22.28%

Apr. 23	Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	MT
Apr. 23	Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	CI

Evolution of the average Target Price on Unity Biotechnology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5e3ee5.hZLFVKjoPLiTDnVwwEcDCmifOF2UUTk-EeKQhFCoBE8.x_jwE9CmbdTWbUNdlXJPQD_GSm25Z1hfQqTcyR3Kcz_p2I4l-7pl0eNFLA~cc3438a9cbee4f2c59761f61585ff15a

Analyst Recommendations on Unity Biotechnology, Inc.

HC Wainwright Adjusts Unity Biotechnology Price Target to $8 From $10, Maintains Buy Rating	Apr. 16	MT
Wedbush Upgrades Unity Biotechnology to Outperform From Neutral, Says Remains in Execution Mode With Advancement of UBX1325; Raises PT to $4 From $2	Nov. 16	MT
Wedbush Downgrades Unity Biotechnology to Neutral From Outperform, Notes Limited Cash Runway, Lack of Other Near-Term Value-Driving Catalysts; Trims PT to $2 From $3	23-06-26	MT
Roth MKM Initiates Unity Biotechnology at Buy With $10 Price Target	23-05-31	MT
Citigroup Adjusts Price Target on Unity Biotechnology to $6 From $5, Maintains Buy Rating	23-05-26	MT
Wedbush Trims Unity Biotechnology's Price Target to $3 From $5 After Model Adjustments, Keeps Outperform Rating	23-04-25	MT
Citigroup Adjusts Price Target on Unity Biotechnology to $5 From $15, Maintains Buy Rating	23-03-28	MT
Wedbush Cuts Unity Biotechnology's PT to $5 From $35 After UBX1325 Study for Wet Age-Related Macular Degeneration Failed to Meet Non-Inferiority Threshold, Keeps Outperform Rating	23-03-28	MT
Mizuho Cuts Price Target on Unity Biotechnology to $12 From $80, Reiterates Buy Rating	22-11-15	MT
Wedbush Trims Unity Biotechnology's Price Target to $35 from $36, Keeps Outperform Rating	22-11-10	MT
HC Wainwright Adjusts Price Target on Unity Biotechnology to $10 From $12, Maintains Buy Rating	22-11-09	MT
Wedbush Boosts Price Target on Unity Biotechnology to $36 From $4, Cites 'Impressive' 24-Week Data for UBX1325, Reverse Stock Split; Outperform Kept	22-11-02	MT
Mizuho Securities Raises Unity Biotechnology's Price Target to $8 From $7, Maintains Buy Rating	22-08-16	MT
Citigroup Adjusts Price Target on Unity Biotechnology to $8 From $5, Reiterates Buy Rating	22-08-15	MT
Citigroup Adjusts Price Target on Unity Biotechnology to $5 From $6, Reiterates Buy Rating	22-05-17	MT
Roth Capital Upgrades Unity Biotechnology to Buy From Neutral, Keeps $4 Price Target	22-01-04	MT
Wedbush Starts Unity Biotechnology at Outperform With $4 Price Target	21-12-15	MT
Mizuho Securities Lifts Unity Biotechnology to Buy From Neutral, Price Target to $7 From $5 on UBX1325 Potential	21-11-10	MT
UNITY BIOTECHNOLOGY : Citigroup Upgrades Unity Biotechnology to Buy From Sell; Price Target is $6	21-06-28	MT
UNITY BIOTECHNOLOGY : HC Wainwright Starts Unity Biotechnology at Buy With $12 Price Target	21-06-07	MT
UNITY BIOTECHNOLOGY : Mizuho Adjusts Price Target on UNITY Biotechnology to $5 From $4, Maintains Neutral Rating	21-03-25	MT
UNITY BIOTECHNOLOGY : Citigroup Downgrades UNITY Biotechnology to Sell From Neutral, Adjusts Price Target to $6 From $5	21-02-16	MT